Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
SAGE-689 by Sage Therapeutics for Unspecified Central Nervous System Disorders: Likelihood of Approval
SAGE-689 is under clinical development by Sage Therapeutics and currently in Phase I for Unspecified Central Nervous System Disorders. According...